SIRPA and neoplasm: Importantly, CD47‐SIRPα blockade with an anti‐CD47 antibody treatment significantly enhanced EGFR‐targeted cancer therapy and elicited much greater tumor growth inhibition than either treatment alone (Figure 7D).